A Study of Amivantamab and Olomorasib Combination Therapy
Phase 1/2
60
about 2.9 years
18+
6 sites in CA, NY, PA +3
What this study is about
This trial is testing the best dose of amivantamab and olomarasib, a combination treatment, for people with metastatic non-small cell lung cancer. The goal is to see how well this combination slows down or stops tumor growth.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Amivantamab
- 2.Take Olomorasib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
amivantamab
Primary: Phase 1: Number of Participants with Adverse Events (AEs) by Severity, Phase 2: Confirmed Objective Response Rate (ORR)
Secondary: Number of Participants with Adverse Events (AEs) by Severity, Phase 2: Disease Control Rate (DCR), Phase 2: Duration of Response (DoR), Phase 2: Overall Survival (OS), Phase 2: Progression-Free Survival (PFS)
Oncology